DMPA + Testosterone | The Contraceptive Pipeline Database

Product Overview

Alternative Name: Depot Medroxyprogesterone Acetate (DMPA) + Testosterone

Development Status: Inactive

Target: Male

Mode: Hormonal

Delivery Type: Injectable, Subdermal

Duration Type: Long-acting

Description: This combined progestin/androgen method for male contraception used testosterone (four 200-mg implants, every 4 months) and DMPA (300 mg every 3 months).

Updated date: May 30, 2018

Vertical Tabs

Product Details

Active Pharmaceutical Ingredient (API): medroxyprogesterone acetate, testosterone

Potential Multi-Purpose Technology (MPT): No

Regimen: Testosterone every 4 months, DMPA every 3 months

Duration: 3 - 5 months

Dose: four 200-mg pellets of testosterone and 300-mg DMPA

Partner: ANZAC Research Institute

Status

Project Phase: Early Development

Project Stage: Phase I

Status Details:
55 healthy men in stable fertile relationships participated in a proof of principle study, with a 12-month contraceptive efficacy period. Sperm density fell rapidly, so 94% of men entered the efficacy phase by 3 months, with only 2 of 55 (3.6%) men not sufficiently suppressed to enter efficacy. No pregnancies occurred in 35.5 person-years. Recovery was complete with medians of 3.6 months to sperm reappearance and 5 months to 20 million sperm/ml.

Programmatic Considerations

Additional Information

Additional Information:
ANZAC Research Institute website

Turner L, et al. (2003) Contraceptive Efficacy of a Depot Progestin and Androgen Combination in Men. The Journal of Clinical Endocrinology & Metabolism. 88(10);4659-67

Download Product Report